Insider transactions

Jaisim Shah

CIK 1242133 · See Remarks · last filed 2024-12-18

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$14.3K
Companies
3
Total Filings
29
Lifetime Open-Market Net
-$670.6K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

PDLI price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O PROTINE DESIGN LAB
37481 MARSTEN DR
NEWARK, CA 94560
Related Filers
PDL BIOPHARMA, INC. — 17 joint filings, latest 2008-04-30
Sorrento Therapeutics, Inc. — 17 joint filings, latest 2021-08-30
Scilex Holding Co — 9 joint filings, latest 2024-12-18
ABBOTT BIOTHERAPEUTICS CORP — 1 joint filings, latest 2008-12-22
CYTRX CORP — 1 joint filings, latest 2009-05-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SCLXW See Remarks 295,215 $0.05 $14.3K $197.2K 8 2024-12-18
Sorrento Therapeutics, Inc. (SRNE) Delisted Director 178,075 $0.00 $89 $399.7K 16 2021-08-30
PDL BIOPHARMA, INC. (PDLI) Delisted SVP, Mktg & Bus. Affairs 15,812 — — -$1.27M 5 2008-04-30

Recent Filings · Page 3 of 3

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2014-09-22 Sorrento Therapeutics, Inc. (SRNE) Delisted Grant (A) — $0 EDGAR
2013-11-26 Sorrento Therapeutics, Inc. (SRNE) Delisted Buy (P) +1,000 $8.7K EDGAR
2013-11-20 Sorrento Therapeutics, Inc. (SRNE) Delisted Buy (P) +1,000 $9.0K EDGAR
2013-10-31 Sorrento Therapeutics, Inc. (SRNE) Delisted Grant (A) — $0 EDGAR
2008-04-30 PDL BIOPHARMA, INC. (PDLI) Delisted Exer (M) +1,251 $10.7K EDGAR
2007-08-17 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) — $0 EDGAR
2007-04-30 PDL BIOPHARMA, INC. (PDLI) Delisted Mixed +260 -$168.4K EDGAR
2007-04-24 PDL BIOPHARMA, INC. (PDLI) Delisted Mixed — -$160.2K EDGAR
2007-04-17 PDL BIOPHARMA, INC. (PDLI) Delisted Mixed — -$293.8K EDGAR
Showing 21–29 of 29
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.